Paper Details

  1. Home
  2. Paper Details

Rotigotine transdermal patch in Chinese patients with early Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study.

Author: AsgharnejadMahnaz, BauerLars, ChenShengdi, DuXinlu, HuXingyue, ShangHui-Fang, SurmannErwin, ZhangZhen-Xin, ZhaoZhongxin

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Rotigotine, a dopamine agonist, is effective and well-tolerated in early-stage Parkinson's disease in Chinese patients.
Paper Details　
Original Abstract of the Article :
Two phase3 studies (SP512; SP513) involving mostly Caucasian patients showed that rotigotine (≤8 mg/24 h) was efficacious and welltolerated in early-stage Parkinson's disease (PD). We report results from a phase 3 study (SP0914/NCT01646268) investigating rotigotine in Chinese patients with early-sta...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.parkreldis.2016.04.022

データ提供：米国国立医学図書館（NLM）

Parkinson's Disease: A Global Health Challenge

Parkinson's disease (PD) is a progressive neurodegenerative disorder that affects millions worldwide. This study investigates the efficacy and safety of rotigotine, a dopamine agonist, in Chinese patients with early-stage PD.

Rotigotine's Effectiveness: A Phase 3 Study

The phase 3 study found that rotigotine was efficacious and well-tolerated in Chinese patients with early-stage PD. This finding provides evidence for the potential of rotigotine as a treatment option for PD in diverse populations.

Managing Parkinson's Disease: A Focus on Personalized Care

The study highlights the importance of personalized treatment strategies for PD. While rotigotine has shown promise, further research is needed to optimize dosing and treatment regimens for individual patients.

Dr.Camel's Conclusion

The journey of a Parkinson's patient can be like a long desert trek, filled with challenges and uncertainties. This study offers a glimmer of hope by demonstrating the effectiveness of rotigotine in Chinese patients with early-stage PD.

Date :
  1. Date Completed 2018-02-05
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

27172830

DOI: Digital Object Identifier

10.1016/j.parkreldis.2016.04.022

Related Literature

Article Analysis
・Effects of rotigotine transdermal patch
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.